| Literature DB >> 29651731 |
Shuang Yang1, Wells W Wu2, Rong-Fong Shen2, Marshall Bern3, John Cipollo4.
Abstract
Mass spectrometric analysis of intact glycopeptides can reveal detailed information aboutEntities:
Keywords: Amidation; Esterification; HILIC; NeuAc2,3; NeuAc2,6; Sialoglycopeptide
Mesh:
Substances:
Year: 2018 PMID: 29651731 PMCID: PMC6744383 DOI: 10.1007/s13361-018-1931-0
Source DB: PubMed Journal: J Am Soc Mass Spectrom ISSN: 1044-0305 Impact factor: 3.109
Figure 1Schematic scheme of glycoprotein modification using a chemoenzymatic solid-phase method. (a) Proteins were conjugated to the solid support (Aminolink resin) via reductive amidation. (b) α2,6-Linked sialic acid, D, E, and C-terminal are derivatized by ethanol in presence of EDC and HBot. (c) α2,6-Linked sialic acid and remaining unmodified D, E, and C-terminal are further modified by ethylenediamine (EDA) in presence of EDC at pH 4–6. (d) Proteins are digested from resin using trypsin after reduction and alkylation. (e) The derivatized glycopeptides are enriched by HILIC SPE chromatography, and flow-through contains non-glycopeptides. (f) Glycopeptides are tested by LC-MS/MS and searched by Byonic and Byologic
Mass Shift of Glycopeptide Modification by Ethyl Esterification and Ethylenediamine (EDA) Amidation. Ethyl Esterification Modifies α2,6-Linked Sialic Acids, While EDA Derivatizes α2,3-Linked Sialic Acids
| Group | Modification | Reagent | Mass shift (Da) |
|---|---|---|---|
| 2,3-Linked sialic acid | Amidation | EDA | 42.058183 |
| 2,6-Linked sialic acid | Esterification | Ethanol | 28.031301 |
| Aspartic acid (D) | Amidation | EDA | 42.058183 |
| Esterification | Ethanol | 28.031301 | |
| Glutamic acid (E) | Amidation | EDA | 42.058183 |
| Esterification | Ethanol | 28.031301 | |
| Protein C-terminal | Esterification | Ethanol | 28.031301 |
| Amidation | EDA | 42.058183 |
Figure 2Oxonium ions of MS/MS on intact glycopeptides after sialic acid derivatization. Sialic acids are present with ethyl and/or ethylenediamine, depending on their linkages
Search Parameters Used in Byonic Software. Options 1, 2, and 3 Were Used to Compare the Modification of D, E, and/or Protein C-Terminal
| Setting | Item | Parameter | Remark |
|---|---|---|---|
| Digestion and instrument | Missed cleavage | 1 | |
| Precursor mass tolerance | 5 ppm | ||
| Fragmentation | QToF & HCD | ||
| Fragment mass tolerance | 0.3 Da | ||
| Spectrum input | Maximum precursor mass | 10 kDa | |
| Maximum # of precursors per MS2 | 1 | ||
| Peptide output | Manual score cut | 10 | |
| Show all | Yes | ||
| Protein output | Protein FDR | 2% | |
| Amino acid modification | Carbamidomethyl | 57.021454 | C, fixed |
| Oxidation | 15.994915 | M, rare | |
| Gln → pyro-Glu | − 17.026549 | Nterm Q, rare | |
| Gln → pyro-Glu | − 18.010565 | Nterm E, rare | |
| Ammonia loss | − 17.026549 | Nterm C, rare | |
| Option 1 | Ethyl esterification | 28.031301 | D, E, Cterm, rare |
| Option 2 | Ethyl esterification | 28.031301 | D, E, Cterm, rare |
| Amidation | 42.058183 | D, E, Cterm, rare | |
| Option 3 | Amidation | 42.058183 | D, E, Cterm, rare |
| Sialic acid modification | a2,-Linked | 28.031301 | |
| a2,3-Linked | 42.058183 |
Figure 3Modification of carboxylic acid on D (aspartic acid) and E (glutamic acid). Acidic amino acids, together with protein C-terminal, are derivatized by ethyl esterification. D or E are also modified by ethylenediamine (EDA) amidation
Relative Abundance of Modified D and E by Ethyl Esterification and EDA, Respectively
| Peptide | Abundance (%) | Missed cleavage | |||
|---|---|---|---|---|---|
| Unmodified | Ethyl | EDA | Total abundance in identified peptides | ||
| CDSSPDSAEDVR | 0.79 | 0.70 | 0.01 | 1.50 | 0 |
| HTLNQIDSVK | 0.39 | 0.00 | 0.01 | 0.40 | 0 |
| LCPDCPLLAPLNDSR | 15.39 | 3.02 | 1.61 | 20.02 | 0 |
| LCPDCPLLAPLNDSRVVHAVALATFNAESNGSYLQLVEISR | 0 | 0.21 | 0.16 | 0.37 | 1 |
| VWPRRPTGEVYDIEIDTLETTCHVLDPTPLANCSVR | 0 | 0.02 | 0.03 | 0.05 | 0 |
| HTFSGVASVESSSGEAFHVGK | 40.96 | 10.00 | 0.03 | 50.99 | 0 |
| HTFSGVASVESSSGEAFHVGKTPIVGQPSIPGGPVR | 1.16 | 2.50 | 0.00 | 3.66 | 1 |
| KLCPDCPLLAPLNDSR | 1.93 | 1.37 | 1.48 | 4.78 | 0 |
| PTGEVYDIEIDTLETTCHVLDPTPLANCSVR | 0.12 | 0.46 | 0.58 | 1.16 | 0 |
| PTGEVYDIEIDTLETTCHVLDPTPLANCSVRQQTQHAVEGDCDIHVLK | 0 | 0.01 | 0.01 | 0.02 | 1 |
| QQTQHAVEGDCDIHVLK | 10.44 | 5.20 | 0.01 | 15.65 | 0 |
| RPTGEVYDIEIDTLETTCHVLDPTPLANCSVR | 0.03 | 0.09 | 0.51 | 0.63 | 1 |
| VVHAVEVALATFNAESNGSYLQLVEISR | 0.03 | 0.25 | 0.15 | 0.43 | 0 |
| VVHAVEVALATFNAESNGSYLQLVEISRAQFVPLPVSVSVEFAVAATDCIAK | 0.03 | 0.14 | 0.15 | 0.32 | 1 |
The peptides containing either D or E are listed, in which they have been modified by ethanol or EDA. Proteins are immobilized on resin prior to derivatization. It is maximum to have one C-terminal esterification or amidation. One missed cleavage is included
Figure 4Fragment ions of sialoglycopeptides (a) without modification and (b) after ethanol-EDA derivatization. (a) Un-modified sialylated glycopeptide, RPTGVYDIEI-DTLETTCHVLDPTPLAN[(NeuAc)3Hex(6)HexNAc(5)]CSVR. (b Ethanol-EDA derivatized sialoglycopeptides. D and E were modified by ethyl esterification, while sialic acid α2,3-linked is labeled by EDA and α2,6-linked by ethanol
Figure 5Identification of glycosites and glycopeptides from bovine fetuin with and without ethanol-EDA derivatization. (a) Three glycosites N[99]CSV, N[156]DSR, and N[176]GSY, containing 93, 61, 99 unique sialoglycopeptides, respectively (in triplicates), on native fetuin after HILIC enrichment. (b) Three glycosites containing 127, 102, and 278 sialoglycopeptides after ethanol-EDA modification. Sialic acid linkage is differentially determined by IntactGIG-HILIC
Identification of Sialoglycopeptides from Human Serum Using IntactGIG Method. α2,6-Linked Sialoglycopeptides Are Abundantly Present in Human Serum
| Glycoprotein | Uniprot ID | Glycosite | Sequence | Mass tag on glycan | Glycan |
|---|---|---|---|---|---|
| Alpha 1-acid glycoprotein | AAB33887 | 56 | R.NeEYnK.S | HexNAc(3)Hex(4) | H4N3 |
| AAB33887 | 103 | R.EnGTISR.Y | HexNAc(2) | N2 | |
| AAB33887 | 33 | M.ALSWVLTVLSLLPLLEAQIPLCANLVPVPITnATLDQITGK.W | HexNAc(2) | N2 | |
| Alpha-2-macroglobulin | P01023 | 70 | R.GnR.S | HexNAc(3)Hex(4) | H4N3 |
| HexNAc(4)Hex(5)NeuAc(2) 56.062582 | S2(2,6)H5N4 | ||||
| HexNAc(4)Hex(5)Fuc(1)NeuAc(2)Na(2) 56.06258067 | S2(2,6)H5N4F1 [2Na] | ||||
| HexNAc(4)Hex(5)NeuAc(1) 28.031275 | S1H5N4 | ||||
| HexNAc(4)Hex(5)Fuc(1)NeuAc(2) 56.062574 | S2(2,6)H5N4F1 | ||||
| HexNAc(2)Hex(7) | H7N2 | ||||
| HexNAc(4)Hex(4) | H4N4 | ||||
| Amyloid-like protein 1 | P51693 | 461 | R.FQVHTHLQVIEERVnQSLGLLDQNPHLAQELRPQIQELLHSEHLGPSELEAPAPGGSSEDK.G | HexNAc(4)Hex(4)NeuAc(1)Na(1) 42.05816434 | S1(2,3)H4N4[Na] |
| Cadherin-2 | P19022 | 338 | R.IVSQAPSTPSPNMFTINnETGdIITVAAGLdREK.V | HexNAc(2)Fuc(1) | H2F1 |
| Endoplasmin | P14625 | 502 | K.LGVIEDHSnRTR.L | HexNAc(4)Hex(5)NeuAc(2) 84.116346 | S2(2,3)H5N4 |
| Haptoglobin | 4WJG | 150 | K.VVLHPnYSQVDIGLIK.L | HexNAc(4)Hex(5)NeuAc(2) 56.062582 | S2(2,6)H5N4 |
| HexNAc(4)Hex(5)NeuAc(2)Na(2) 70.08947067 | S1(2,6)S1(2,3)H5N4[2Na] | ||||
| Hemopexin | P02790 | 453 | K.ALPQPQnVTSLLGCTH.- | HexNAc(4)Hex(5)NeuAc(2) 56.062582 | S2(2,6)H5N4 |
| 187 | R.SWPAVGnCSSALR.W | HexNAc(4)Hex(5)NeuAc(2) 56.062582 | S2(2,6)H5N4 | ||
| Integrin alpha-2 | P17301 | 1074 | K.GEYFVnVTTR.I | HexNAc(2)Hex(3) | H3N2 |
| Integrin beta-1 | P05556 | 94 | K.NKnVTNR.S | HexNAc(4)Hex(5)Fuc(1)NeuAc(1) 28.031267 | S1(2,6)H5N4F1 |
| Titin | Q8WZ42 | 21153 | R.AnK.T | HexNAc(4)Hex(5)NeuAc(2) 56.062582 | S2(2,6)H5N4 |
| R.AnK.T | HexNAc(4)Hex(5)Fuc(1)NeuAc(2)Na(2) 70.08946267 | S1(2,6)S1(2,3)H5N4F1[2Na] |
N, hexNAc; H, hexose; F, fucose; S, NeuAc
Figure 6MS/MS spectra of one sialoglycopeptide identified from human serum haptoglobin. (a) Native sialoglycopeptides without derivatization. (b) Eth-EDA derivatized α2,6-linked sialoglycopeptide, VVLHP[S2(2,6)H5N4]YSQVDIGLIK